Genetic screening in Parkinson*s Disease in order to identify patients who can participate in clinical trials with new targeted therapies

Genetic screening in Parkinson*s Disease in order to identify patients who can participate in clinical trials with new targeted therapies - GBA1 and LRRK2 screening

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45734

Enrollment

1000

Registered

2017-04-04

Start date

2017-04-12

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

movement disorder Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Signed informed consent prior to any study-mandated procedure; 2. Diagnosis of Parkinson*s Disease, diagnosed by a neurologist; 3. Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Sequence of the GBA1 gene Presence of 7 specific mutations in the LRRK2 gene	—

Secondary

Measure	Time frame
Database of genotyped PD patients, for future research on PD	—

Countries

Netherlands

Outcome results